Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 12th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

Regarding the Series 12 stock acquisition rights allocated to EVO FUND, rights covering 1,430,000 shares were exercised between 2 November and 19 November 2026, reducing the number of unexercised rights from 41,100 to 26,800. The exercise price was ¥64–69 per share and was adjusted based on the share price.

Worth reading
69In focus
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
1430000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Large-scale exercise of the 12th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment provision)

Who receives how much

Shares delivered since the beginning of the month: 1,430,000 shares (1,430,000 new shares and 0 treasury shares transferred)

EVO FUND (the allottee at the time of issuance on 7 August 2026)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
—Rate of increase
20,195,000 shares21,625,000Shares

Shares delivered since the beginning of the month: 1,430,000 shares. No ratio to the 20,195,000 shares issued as of the end of the previous month was stated.

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price in the exercise status was ¥64–69 per share. The specific terms and floor of the adjustment clause were Not disclosed.
Number of Stock Acquisition Rights
Total issued: 100,000 rights. Unexercised rights were 41,100 as of the end of the previous month and 26,800 at present.
Most recent equity financing
7 August 2026: Issuance of Series 12 stock acquisition rights through a third-party allotment (with an exercise price adjustment clause) and Series 3 unsecured bonds (privately placed bonds) (individual amounts Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalLarge-scale exercise of the 12th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment provision)
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 1,430,000 shares (1,430,000 new shares and 0 treasury shares transferred)
Intended allotteeEVO FUND (the allottee at the time of issuance on 7 August 2026)
Dilution RateShares delivered since the beginning of the month: 1,430,000 shares. No ratio to the 20,195,000 shares issued as of the end of the previous month was stated.
Total number of issued shares20,195,000 shares (as of the end of the previous month) → 21,625,000 shares (simple calculation)
Exercise priceThe exercise price in the exercise status was ¥64–69 per share. The specific terms and floor of the adjustment clause were Not disclosed.
Number of Stock Acquisition RightsTotal issued: 100,000 rights. Unexercised rights were 41,100 as of the end of the previous month and 26,800 at present.
Most recent equity financing7 August 2026: Issuance of Series 12 stock acquisition rights through a third-party allotment (with an exercise price adjustment clause) and Series 3 unsecured bonds (privately placed bonds) (individual amounts Not disclosed)
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the bulk exercise of these stock acquisition rights during the period from 2 November to 19 November 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 12th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori